Relapse and progression after CAR-T cell therapy in large B-cell lymphoma: Patterns, mechanisms, and salvage strategies.
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for large B-cell lymphoma (LBCL), particularly in the relapsed or refractory. However, relapse after CAR-T cell therapy remains a major barrier to durable remission and long-term survival because post-CAR-T relapse is biologically an...